On June 8, 2022 Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, reported that Dr. Joseph Tucker, Chief Executive Officer of Enveric, will participate in three upcoming conferences (Press release, Enveric Biosciences, JUN 8, 2022, View Source [SID1234615758]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A.G.P.’s Summer Healthcare Conference

Gravitas’ 3rd Los Angeles Summit

H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

For more information about the conference, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate representatives, or send an email to A.G.P. at [email protected], Gravitas at [email protected], H.C. Wainwright at [email protected] or KCSA Strategic Communications at [email protected].

On June 8, 2022 Alvotech Holdings SA ("Alvotech SA"), a global biotech company focused exclusively on developing and manufacturing biosimilar drugs for patients worldwide, and Oaktree Acquisition Corp. II ("OACB") (NYSE: OACB), a special purpose acquisition company sponsored by a subsidiary of Oaktree Capital Management, LP ("Oaktree"), reported that their previously announced business combination between Alvotech SA, OACB and the legal entity named Alvotech, previously named Alvotech Lux Holdings SAS, with Alvotech as its surviving entity (the "Business Combination") was approved by the shareholders of OACB in (Press release, Alvotech, JUN 8, 2022, View Source [SID1234615774])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

It is expected that the Business Combination will be completed (on or about) June 15, 2022, subject to the satisfaction of all other applicable closing conditions. Alvotech’s common stock is expected to trade under the ticker symbol "ALVO" on the Nasdaq Stock Market in New York and the Nasdaq First North Growth Market in Reykjavik, and Alvotech’s warrants are expected to trade on the Nasdaq Stock Market in New York under the mnemo "ALVOW".

"This is an exciting time for the Alvotech team, our partners, and anyone who wants more affordable, high-quality biologic medicines," said Robert Wessman, Founder and Chairman of the Board of Alvotech. "Since the company was founded a decade ago, we have been dedicated to expanding patient access to life-changing treatments."

"Alvotech becomes a publicly traded company at a pivotal time for the healthcare industry globally, when demand for increased affordability and accessibility has never been greater," said Zaid Pardesi, Director Financier and Head of M&A, Oaktree Acquisition Corp II. "We are proud of this partnership with a company that is transforming the lives of patients and improving the sustainability of healthcare systems, and we look forward to continuing to work alongside the Alvotech team to achieve their goal of become a leading provider of biosimilars in all major global markets."

On June 8, 2022 Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, reported that it will have two poster presentations demonstrating that its novel protease biosensor diagnostic platform can detect hepatocellular carcinoma (HCC) at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 (ILC) (Press release, Glympse Bio, JUN 8, 2022, View Source [SID1234615790]). The conference will be held from June 22-26 at ExCeL in London, United Kingdom.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HCC is the fifth leading cancer globally, and non-invasive diagnostic options are needed to improve early diagnosis for better treatment outcomes. Glympse has developed a novel diagnostic platform technology that utilizes biosensors and machine learning to measure protease activity in plasma samples and will present two analyses demonstrating the platform’s ability to detect HCC. In poster #SAT564, Glympse will present results from a study of two independently tested, diverse cohorts of patients (n = 94) with known HCC vs. healthy controls, which determined Glympse’s platform was effective at detecting HCC (AUC ≥ 0.94). In the second poster (#FRI236), Glympse utilized the platform technology to differentiate between plasma samples with diagnosed HCC and without HCC but with cirrhosis (n = 43 and 26, respectively). Results showed that the protease activity platform was effective at HCC detection (AUC = 0.93) and has potential future utility for early diagnosis, considering 72% of the HCC cases had early-stage tumors.

"Our data demonstrate that the Glympse protease-based diagnostic platform is showing very promising data in the early detection of HCC," said Tram Tran, M.D., Chief Medical Officer of Glympse. "With proper validation, this technology could be used in surveillance strategies for earlier, easier, and more accurate diagnosis of HCC."

"The Glympse diagnostic platform continues to demonstrate highly accurate predictive capabilities for disease detection," said Caroline Loew, Ph.D., Chief Executive Officer of Glympse. "Following our presentation at AASLD, in which we were able to predict NASH vs. healthy patients with 97% accuracy, these data at the EASL conference showcase the platform’s ability to highly accurately detect HCC. We look forward to the continued validation of this platform, and of the measurement of protease activity, to accurately diagnose and monitor disease for patients in need."

Information regarding the two poster presentations can be found below.

Title: Novel and accurate measurement of differential protease activity in diagnosed HCC patients compared to non-HCC cirrhotic patients
Presented By: Amit Singal, M.D.
Poster Session: Non-invasive assessment of liver disease except NAFLD
Time/Date: June 24, 2022, 9:00 a.m. – 6:30 p.m. BST
Abstract #: FRI236

Title: Measurement of protease activity using novel plasma biosensors can accurately detect HCC
Presented By: Tram Tran, M.D.
Poster Session: Liver tumours: Clinical aspects except therapy
Time/Date: June 25, 2022, 9:00 a.m. – 6:30 p.m. BST
Abstract #: SAT564

On June 8, 2022 CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), reported its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types (Press release, CureVac, JUN 8, 2022, View Source [SID1234615806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The addition of Frame’s technology and talent to CureVac’s oncology research complements our ability to identify and validate promising neoantigens for our mRNA cancer vaccine programs," said Franz-Werner Haas, Chief Executive Officer of CureVac. "The bioinformatics platform developed by Frame’s researchers has the potential to identify a broad panel of neoantigens that go beyond conventional neoantigens and could strongly increase the likelihood of developing highly effective cancer vaccines. We are excited to join forces with the innovative Frame Cancer Therapeutics team and combine their bioinformatics capabilities with our own mRNA expertise to potentially deliver a new class of cancer vaccines."

Frame’s FramePro platform identifies structural changes within the cancer genome that give rise to new open reading frames. These new open reading frames result in novel proteins that are absent in healthy tissues and can thereby be recognized as foreign by the immune system. Although these genetic changes are highly specific to individuals, the resulting neoantigenic proteins may be shared among many patients, potentially enabling development of more broadly applicable cancer vaccines.

An additional application of Frame’s technology is the development of personalized cancer vaccines, thereby leveraging the full antigenic potential of a tumor. In December 2021, regulators in the Netherlands approved Frame’s clinical trial protocol to evaluate this approach based on a peptide vaccine in 15 patients with non-small cell lung cancer. CureVac will refocus development of personalized cancer vaccines on an mRNA modality.

"We are very enthusiastic about the great synergies between our content-driven approach in antigen discovery and validation and CureVac’s extensive experience with mRNA vaccine development," said Ronald Plasterk, Founder and CEO of Frame Cancer Therapeutics. "The resulting vaccines could greatly enhance our ability to activate the human immune system against cancer, both in a personalized and off-the-shelf manner."

The total consideration for the acquisition of Frame Therapeutics is valued at €32 million. It will be paid in CureVac shares. Following a 50 percent upfront payment, the residual amount will be split across two project milestone driven steps. CureVac will expand the antigen discovery and validation activities at the Amsterdam Science Park.

On June 8, 2022 C&Cure (CEO Min Jeong-jun and Park Joong-gon), which develops a bacterial anticancer drug platform and radioactive pharmaceuticals, reported the company has completed Series B bridge investment (Press release, CNCure, JUN 8, 2022, View Source [SID1234649033]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

It has been one year since it was selected for Series A investment (KRW 6.5 billion) and investment-linked Ministry of Trade, Industry and Energy project (support amount KRW 2.5 billion) in February last year.

According to C&Cure on the 8th, existing institutional investors DT&Investment and ID Ventures made follow-up investments in the Series B bridge investment, and Hana Ventures participated as a new institutional investor.

Including the 2019 seed round (KRW 2.3 billion), the total amount raised up to this stage amounts to KRW 13 billion.

Kang Hoon-mo, an executive director at Hana Ventures who led this investment, said, "The investment point is the high research capabilities of C-level executives with world-class global competitiveness."

The funds raised will be used for the development of a bacterial anticancer drug currently underway in the United States (under contract with a US CDMO) and for the development of a radiopharmaceutical drug (in the first clinical trial underway with the Ministry of Food and Drug Safety).

The company plans to apply for an additional clinical trial of a radiopharmaceutical for the early diagnosis of malignant melanoma in the second half of this year.

C&Cure is a company established in 2019 by professors at Chonnam National University College of Medicine, and is conducting a national research project with a total budget of 8 billion won hosted by the Ministry of Trade, Industry and Energy and the Ministry of Science and ICT.

Professor Min (Department of Nuclear Medicine, photo), Professor Hong Young-jin (Microbiology), and Professor Kim Dong-yeon (College of Pharmacy, Gyeongsang National University) who are co-representatives are leading the research and development.